按月查看: December 2009

It Takes a Community

The winter holidays and the New Year are approaching. There are multi-hued lights, decorated trees, candles, menorahs, holiday music and wreathes. This is also the time of the year for television, mail, radio and other requests for contributions to various

文章分类 Issue 60 - Spring 2010

From the Top

I was in Tennessee this week, seeing the colors of the trees burn across the ridges, and feeling the fall induced opportunity to feel gratitude. As you get this, we’ll all be deep into the holidays and winter, giving us

文章分类 Issue 60 - Spring 2010

How Patients and Patient Advocacy Groups Get New Treatments Approved

Did you know that it takes an average of $800 Million and 8 years for a drug manufacturer to complete research and development, prove safety and efficacy in multiple clinical trials? (read more at http://bit.ly/6wMxgk) More so, in the arena

文章分类 Issue 60 - Spring 2010

Public Database Is Urged to Monitor Drug Safety

What could be done to prevent another Vioxx? This pain medication for arthritis became a blockbuster after its introduction in 1999, only to be taken off the market in 2004 when a study linked the drug to an increased risk

文章分类 Around the Globe

A Genetics Company Fails, Its Research Too Complex

DeCode Genetics, a pioneering company that used the Icelandic population as its guinea pigs in detecting disease-causing mutations, filed for bankruptcy on Tuesday.

文章分类 Around the Globe

Rituximab offers hope: Treatment provides steroid-sparing response in refractory bullous pemphigoid

Durham, N.C. — Dermatologists at Duke University using rituximab (Rituxan, Genentech) for the management of patients with treatment-resistant bullous pemphigoid (BP) have found that this anti-CD20 monoclonal antibody allows corticosteroid-dependent patients to successfully taper their immunosuppressive therapy.

文章分类 Around the Globe

Current Treatment of Autoimmune Blistering Diseases

Autoimmune bullous diseases are a heterogeneous group of disorders that can be subdivided according to the level of split formation in the intraepidermal blistering pemphigus diseases and subepidermal bullous disorders.

文章分类 Around the Globe
JOIN TODAY!
The P/P Registry has been approved by the Western Institutional Review Board (WIRB) and is actively enrolling participants.

ENGLISH VERSION

SPANISH VERSION